Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ivacaftor in People with Cystic Fibrosis and a 3849+10kb C→T or D1152H Residual Function Mutation.
Kerem E, Cohen-Cymberknoh M, Tsabari R, Wilschanski M, Reiter J, Shoseyov D, Gileles-Hillel A, Pugatsch T, Davies JC, Short C, Saunders C, DeSouza C, Sullivan JC, Doyle JR, Chandarana K, Kinnman N. Kerem E, et al. Among authors: wilschanski m. Ann Am Thorac Soc. 2021 Mar;18(3):433-441. doi: 10.1513/AnnalsATS.202006-659OC. Ann Am Thorac Soc. 2021. PMID: 33095038 Free PMC article. Clinical Trial.
Cystic fibrosis, pregnancy, and recurrent, acute pancreatitis.
Virgilis D, Rivkin L, Samueloff A, Picard E, Goldberg S, Faber J, Kerem E, Wilschanski M. Virgilis D, et al. Among authors: wilschanski m. J Pediatr Gastroenterol Nutr. 2003 Apr;36(4):486-8. doi: 10.1097/00005176-200304000-00013. J Pediatr Gastroenterol Nutr. 2003. PMID: 12658041 No abstract available.
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.
Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M. Kerem E, et al. Among authors: wilschanski m. Lancet. 2008 Aug 30;372(9640):719-27. doi: 10.1016/S0140-6736(08)61168-X. Epub 2008 Aug 20. Lancet. 2008. PMID: 18722008 Clinical Trial.
Evidence of intestinal inflammation in patients with cystic fibrosis.
Werlin SL, Benuri-Silbiger I, Kerem E, Adler SN, Goldin E, Zimmerman J, Malka N, Cohen L, Armoni S, Yatzkan-Israelit Y, Bergwerk A, Aviram M, Bentur L, Mussaffi H, Bjarnasson I, Wilschanski M. Werlin SL, et al. Among authors: wilschanski m. J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):304-8. doi: 10.1097/MPG.0b013e3181d1b013. J Pediatr Gastroenterol Nutr. 2010. PMID: 20512061
Small molecules to treat cystic fibrosis.
Wilschanski M. Wilschanski M. Proc Am Thorac Soc. 2010 Nov;7(6):399-403. doi: 10.1513/pats.201001-012AW. Proc Am Thorac Soc. 2010. PMID: 21030520 Review.
Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis.
Kerem E, Wilschanski M, Miller NL, Pugatsch T, Cohen T, Blau H, Rivlin J, Shoseyov D, Reha A, Constantine S, Ajayi T, Hirawat S, Elfring GL, Peltz SW, Miller LL. Kerem E, et al. Among authors: wilschanski m. J Cyst Fibros. 2011 May;10(3):193-200. doi: 10.1016/j.jcf.2011.02.003. Epub 2011 Apr 2. J Cyst Fibros. 2011. PMID: 21459051 Free article.
New drugs for cystic fibrosis.
Wilschanski M, Kerem E. Wilschanski M, et al. Expert Opin Investig Drugs. 2011 Sep;20(9):1285-92. doi: 10.1517/13543784.2011.600304. Epub 2011 Jul 11. Expert Opin Investig Drugs. 2011. PMID: 21745147 Review.
The cystic fibrosis of exocrine pancreas.
Wilschanski M, Novak I. Wilschanski M, et al. Cold Spring Harb Perspect Med. 2013 May 1;3(5):a009746. doi: 10.1101/cshperspect.a009746. Cold Spring Harb Perspect Med. 2013. PMID: 23637307 Free PMC article. Review.
Nasal potential difference measurements in diagnosis of cystic fibrosis: an international survey.
Naehrlich L, Ballmann M, Davies J, Derichs N, Gonska T, Hjelte L, van Konigsbruggen-Rietschel S, Leal T, Melotti P, Middleton P, Tümmler B, Vermeulen F, Wilschanski M; ECFS Diagnostic Network Working Group. Naehrlich L, et al. Among authors: wilschanski m. J Cyst Fibros. 2014 Jan;13(1):24-8. doi: 10.1016/j.jcf.2013.08.006. Epub 2013 Sep 7. J Cyst Fibros. 2014. PMID: 24022019 Free article.
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.
Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; Cystic Fibrosis Ataluren Study Group. Kerem E, et al. Among authors: wilschanski m. Lancet Respir Med. 2014 Jul;2(7):539-47. doi: 10.1016/S2213-2600(14)70100-6. Epub 2014 May 15. Lancet Respir Med. 2014. PMID: 24836205 Free PMC article. Clinical Trial.
Genetic and electrophysiological characteristics of recurrent acute pancreatitis.
Werlin S, Konikoff FM, Halpern Z, Barkay O, Yerushalmi B, Broide E, Santo E, Shamir R, Shaoul R, Shteyer E, Yaakov Y, Cohen M, Kerem E, Ruszniewski P, Masson E, Ferec C, Wilschanski M. Werlin S, et al. Among authors: wilschanski m. J Pediatr Gastroenterol Nutr. 2015 May;60(5):675-9. doi: 10.1097/MPG.0000000000000623. J Pediatr Gastroenterol Nutr. 2015. PMID: 25383785
Cystic fibrosis and the role of gastrointestinal outcome measures in the new era of therapeutic CFTR modulation.
Bodewes FA, Verkade HJ, Taminiau JA, Borowitz D, Wilschanski M; Working group C​ystic Fibrosis and Pancreatic Disease of the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN). Bodewes FA, et al. Among authors: wilschanski m. J Cyst Fibros. 2015 Mar;14(2):169-77. doi: 10.1016/j.jcf.2015.01.006. Epub 2015 Feb 10. J Cyst Fibros. 2015. PMID: 25677689 Free article. Review.
The impact of a national population carrier screening program on cystic fibrosis birth rate and age at diagnosis: Implications for newborn screening.
Stafler P, Mei-Zahav M, Wilschanski M, Mussaffi H, Efrati O, Lavie M, Shoseyov D, Cohen-Cymberknoh M, Gur M, Bentur L, Livnat G, Aviram M, Alkrinawi S, Picard E, Prais D, Steuer G, Inbar O, Kerem E, Blau H. Stafler P, et al. Among authors: wilschanski m. J Cyst Fibros. 2016 Jul;15(4):460-6. doi: 10.1016/j.jcf.2015.08.007. Epub 2015 Sep 16. J Cyst Fibros. 2016. PMID: 26386752 Free article.
Ataluren for the treatment of cystic fibrosis.
Shoseyov D, Cohen-Cymberknoh M, Wilschanski M. Shoseyov D, et al. Among authors: wilschanski m. Expert Rev Respir Med. 2016 Apr;10(4):387-391. doi: 10.1586/17476348.2016.1150181. Epub 2016 Feb 24. Expert Rev Respir Med. 2016. PMID: 26840186
Treatment of cystic fibrosis in low-income countries.
Cohen-Cymberknoh M, Shoseyov D, Breuer O, Shamali M, Wilschanski M, Kerem E. Cohen-Cymberknoh M, et al. Among authors: wilschanski m. Lancet Respir Med. 2016 Feb;4(2):91-2. doi: 10.1016/S2213-2600(15)00507-X. Lancet Respir Med. 2016. PMID: 26868623 No abstract available.
Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor.
Mesbahi M, Shteinberg M, Wilschanski M, Hatton A, Nguyen-Khoa T, Friedman H, Cohen M, Escabasse V, Le Bourgeois M, Lucidi V, Sermet-Gaudelus I, Bassinet L, Livnat G. Mesbahi M, et al. Among authors: wilschanski m. J Cyst Fibros. 2017 Jan;16(1):45-48. doi: 10.1016/j.jcf.2016.08.006. Epub 2016 Sep 20. J Cyst Fibros. 2017. PMID: 27659740 Free article.
Diagnosis of Cystic Fibrosis in Screened Populations.
Farrell PM, White TB, Howenstine MS, Munck A, Parad RB, Rosenfeld M, Sommerburg O, Accurso FJ, Davies JC, Rock MJ, Sanders DB, Wilschanski M, Sermet-Gaudelus I, Blau H, Gartner S, McColley SA. Farrell PM, et al. Among authors: wilschanski m. J Pediatr. 2017 Feb;181S:S33-S44.e2. doi: 10.1016/j.jpeds.2016.09.065. J Pediatr. 2017. PMID: 28129810 Free article.
Cystic fibrosis: a gastrointestinal cancer syndrome.
Slae M, Wilschanski M. Slae M, et al. Among authors: wilschanski m. Lancet Oncol. 2018 Jun;19(6):719-720. doi: 10.1016/S1470-2045(18)30250-X. Epub 2018 Apr 26. Lancet Oncol. 2018. PMID: 29706381 No abstract available.
Primary sclerosing cholangitis is associated with abnormalities in CFTR.
Werlin S, Scotet V, Uguen K, Audrezet MP, Cohen M, Yaakov Y, Safadi R, Ilan Y, Konikoff F, Galun E, Mizrahi M, Slae M, Sayag S, Cohen-Cymberknoh M, Wilschanski M, Ferec C. Werlin S, et al. Among authors: wilschanski m. J Cyst Fibros. 2018 Sep;17(5):666-671. doi: 10.1016/j.jcf.2018.04.005. Epub 2018 May 26. J Cyst Fibros. 2018. PMID: 29807875 Free article.
Nasal potential difference in suspected cystic fibrosis patients with 5T polymorphism.
Aalbers BL, Yaakov Y, Derichs N, Simmonds NJ, De Wachter E, Melotti P, De Boeck K, Leal T, Tümmler B, Wilschanski M, Bronsveld I. Aalbers BL, et al. Among authors: wilschanski m. J Cyst Fibros. 2020 Jul;19(4):627-631. doi: 10.1016/j.jcf.2019.07.001. Epub 2019 Jul 19. J Cyst Fibros. 2020. PMID: 31331863 Free article.
Prevention of malnutrition in cystic fibrosis.
Slae M, Wilschanski M. Slae M, et al. Among authors: wilschanski m. Curr Opin Pulm Med. 2019 Nov;25(6):674-679. doi: 10.1097/MCP.0000000000000629. Curr Opin Pulm Med. 2019. PMID: 31567328
Hijab Pin Ingestions.
Yogev D, Mahameed F, Gileles-Hillel A, Millman P, Davidovics Z, Hashavya S, Rekhtman D, Wilschanski M, Berkun Y, Slae M. Yogev D, et al. Among authors: wilschanski m. Pediatrics. 2020 Jun;145(6):e20193472. doi: 10.1542/peds.2019-3472. Epub 2020 May 8. Pediatrics. 2020. PMID: 32385133
A Green Light for Stop Mutations.
Cohen-Cymberknoh M, Slae M, Wilschanski M. Cohen-Cymberknoh M, et al. Among authors: wilschanski m. Am J Respir Cell Mol Biol. 2021 May;64(5):531-532. doi: 10.1165/rcmb.2021-0060ED. Am J Respir Cell Mol Biol. 2021. PMID: 33705685 Free PMC article. No abstract available.
Cystic fibrosis and the gut.
Slae M, Wilschanski M. Slae M, et al. Among authors: wilschanski m. Frontline Gastroenterol. 2020 Oct 27;12(7):622-628. doi: 10.1136/flgastro-2020-101610. eCollection 2021. Frontline Gastroenterol. 2020. PMID: 34917319 Free PMC article.
3.22 Nutrition in Cystic Fibrosis.
Slae M, Wilschanski M. Slae M, et al. Among authors: wilschanski m. World Rev Nutr Diet. 2022;124:374-381. doi: 10.1159/000517004. Epub 2022 Mar 3. World Rev Nutr Diet. 2022. PMID: 35240644 Review. No abstract available.
Sleep disorders in children with celiac disease: a prospective study.
Reiter J, Abuelhija H, Slae M, Millman P, Davidovics Z, Chaimov E, Gileles-Hillel A, Wilschanski M. Reiter J, et al. Among authors: wilschanski m. J Clin Sleep Med. 2023 Mar 1;19(3):591-594. doi: 10.5664/jcsm.10396. J Clin Sleep Med. 2023. PMID: 36546369 Free PMC article.
Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.
Sadras I, Kerem E, Livnat G, Sarouk I, Breuer O, Reiter J, Gileles-Hillel A, Inbar O, Cohen M, Gamliel A, Stanleigh N, Gunawardena T, Bartlett C, Gonska T, Moraes T, Eckford PDW, Bear CE, Ratjen F, Kerem B, Wilschanski M, Shteinberg M, Cohen-Cymberknoh M. Sadras I, et al. Among authors: wilschanski m. J Cyst Fibros. 2023 Nov;22(6):1062-1069. doi: 10.1016/j.jcf.2023.06.001. Epub 2023 Jun 16. J Cyst Fibros. 2023. PMID: 37331863
The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype.
Augarten A, Ben Tov A, Madgar I, Barak A, Akons H, Laufer J, Efrati O, Aviram M, Bentur L, Blau H, Paret G, Wilschanski M, Kerem BS, Yahav Y. Augarten A, et al. Among authors: wilschanski m. Eur J Gastroenterol Hepatol. 2008 Mar;20(3):164-8. doi: 10.1097/MEG.0b013e3282f36d04. Eur J Gastroenterol Hepatol. 2008. PMID: 18301294
Genetic modifiers of liver disease in cystic fibrosis.
Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; Gene Modifier Study Group. Bartlett JR, et al. Among authors: wilschanski m. JAMA. 2009 Sep 9;302(10):1076-83. doi: 10.1001/jama.2009.1295. JAMA. 2009. PMID: 19738092 Free PMC article.
Preconditioning allows engraftment of mouse and human embryonic lung cells, enabling lung repair in mice.
Rosen C, Shezen E, Aronovich A, Klionsky YZ, Yaakov Y, Assayag M, Biton IE, Tal O, Shakhar G, Ben-Hur H, Shneider D, Vaknin Z, Sadan O, Evron S, Freud E, Shoseyov D, Wilschanski M, Berkman N, Fibbe WE, Hagin D, Hillel-Karniel C, Krentsis IM, Bachar-Lustig E, Reisner Y. Rosen C, et al. Among authors: wilschanski m. Nat Med. 2015 Aug;21(8):869-79. doi: 10.1038/nm.3889. Epub 2015 Jul 13. Nat Med. 2015. PMID: 26168294
188 results